Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 78, Issue 2, Pages 142-152Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.04.079
Keywords
chronic kidney disease; clinical trial; finerenone; mineralocorticoid receptor antagonist; new-onset atrial fibrillation; type 2 diabetes
Categories
Funding
- Bayer AG, Berlin, Germany
- Bayer
- Novartis
- Vifor Pharma
- Medtronic
- Servier
- Amgen
- Boehringer Ingelheim
- European Union
- Novo Nordisk
- Vascular Dynamics
- U.S. Veterans Administration
- National Institutes of Health
- AstraZeneca
- National Medical Research Council of Singapore
- Boston Scientific
- Roche Diagnostics
- Abbott Vascular
Ask authors/readers for more resources
In the FIDELIO-DKD study, finerenone was found to reduce the risk of new-onset atrial fibrillation/flutter in patients with CKD and T2D. The effect on kidney or cardiovascular events was not significantly impacted by baseline history of atrial fibrillation/flutter.
BACKGROUND Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models. OBJECTIVES This work aims to examine the effect of finerenone on new-onset AFF and cardiorenal effects by history of AFF in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study. METHODS Patients with CKD and T2D were randomized (1:1) to finerenone or placebo. Eligible patients had a urine albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g, an estimated glomerular filtration rate (eGFR) >= 25 to <75 ml/min/1.73 m(2) and received optimized doses of renin-angiotensin system blockade. Effect on new-onset AFF was evaluated as a pre-specified outcome adjudicated by an independent cardiologist committee. The primary composite outcome (time to first onset of kidney failure, a sustained decrease of >= 40% in eGFR from baseline, or death from renal causes) and key secondary outcome (time to first onset of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) were analyzed by history of AFF. RESULTS Of 5,674 patients, 461 (8.1%) had a history of AFF. New-onset AFF occurred in 82 (3.2%) patients on finerenone and 117 (4.5%) patients on placebo (hazard ratio: 0.71; 95% confidence interval: 0.53-0.94; p = 0.016). The effect of finerenone on primary and key secondary kidney and cardiovascular outcomes was not significantly impacted by baseline AFF (interaction p value: 0.16 and 0.85, respectively). CONCLUSIONS In patients with CKD and T2D, finerenone reduced the risk of new-onset AFF. The risk of kidney or cardiovascular events was reduced irrespective of history of AFF at baseline. (EudraCT 2015-000990-11 [A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease]; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease [FIDELIO-DKD]; NCT02540993)((C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available